Last reviewed · How we verify
Mometasone Nasal Spray
Mometasone Nasal Spray is a Small molecule drug developed by Washington University School of Medicine. It is currently FDA-approved. Also known as: Nasonex, NasometinTM, Sandoz, Mometasone furoate aqueous nasal spray, NASONEX.
At a glance
| Generic name | Mometasone Nasal Spray |
|---|---|
| Also known as | Nasonex, NasometinTM, Sandoz, Mometasone furoate aqueous nasal spray, NASONEX, Mometasone furoate nasal spray |
| Sponsor | Washington University School of Medicine |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Long-term Safety and Efficacy Evaluation of Lunsekimig in Adult Participants With Chronic Rhinosinusitis With Nasal Polyps (CRSwNP) Who Completed a Previous Lunsekimig CRSwNP Study (PHASE2)
- A Phase 3 Study to Assess the Efficacy, Safety, and Tolerability of Itepekimab (Anti-IL-33 mAb) in Participants With Inadequately-controlled Chronic Rhinosinusitis With Nasal Polyps (PHASE3)
- A Phase 3 Study to Assess the Efficacy, Safety, and Tolerability of Itepekimab (Anti-IL-33 mAb) in Participants With Inadequately-controlled Chronic Rhinosinusitis With Nasal Polyps (PHASE3)
- Long-term Safety and Efficacy of TQH2722 Injection in the Treatment of Chronic Sinusitis With or Without Nasal Polyps (PHASE2)
- A Proof-of-concept Study of Lunsekimig Compared With Placebo in Adults With Chronic Rhinosinusitis With Nasal Polyps (PHASE2)
- Research on Underlying Causes of Long-term Use of Nasal Decongestants and the Structured Withdrawal of the Decongestant (PHASE4)
- A Extension Clinical Study of TQC2731 Injection in the Treatment of Chronic Sinusitis With Nasal Polyps (PHASE2)
- A Proof-of-Concept Study to Assess the Efficacy, Safety and Tolerability of Itepekimab (Anti--IL-33 mAb) in Participants With Chronic Rhinosinusitis Without Nasal Polyps (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Mometasone Nasal Spray CI brief — competitive landscape report
- Mometasone Nasal Spray updates RSS · CI watch RSS
- Washington University School of Medicine portfolio CI
Frequently asked questions about Mometasone Nasal Spray
What is Mometasone Nasal Spray?
Mometasone Nasal Spray is a Small molecule drug developed by Washington University School of Medicine.
Who makes Mometasone Nasal Spray?
Mometasone Nasal Spray is developed and marketed by Washington University School of Medicine (see full Washington University School of Medicine pipeline at /company/washington-university-school-of-medicine).
Is Mometasone Nasal Spray also known as anything else?
Mometasone Nasal Spray is also known as Nasonex, NasometinTM, Sandoz, Mometasone furoate aqueous nasal spray, NASONEX, Mometasone furoate nasal spray.
What development phase is Mometasone Nasal Spray in?
Mometasone Nasal Spray is FDA-approved (marketed).
Related
- Manufacturer: Washington University School of Medicine — full pipeline
- Also known as: Nasonex, NasometinTM, Sandoz, Mometasone furoate aqueous nasal spray, NASONEX, Mometasone furoate nasal spray
- Compare: Mometasone Nasal Spray vs similar drugs
- Pricing: Mometasone Nasal Spray cost, discount & access